IP Library › Granted Patent US 7,700,097
Granted Patent B2
US 7,700,097 · App. 10/880,320 · Granted Apr 20, 2010

Purification and preferential synthesis of binding molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,097
App. No.
10/880,320
Granted
Apr 20, 2010
Kind
B2
Abstract

The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.

Claims (43)

1. A composition comprising polypeptide dimers having at least two antigen binding sites and at least two polypeptide chains, wherein said at least two polypeptide chains each comprise a complete Ig heavy chain, and a chimeric hinge,

wherein said chimeric hinge connects the CH1 and the CH2 domain of the Ig heavy chain, and

wherein greater than 50% of the polypeptide dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage, and

wherein amino acids at positions 226-242 (Kabat numbering) comprise: (i) the human IgG1 upper hinge region sequence EPKSCDKTHT (SEQ ID NO:2) or the human IgG4 upper hinge region sequence ESKYGPP (SEQ ID NO:50) at Kabat hinge positions 226-238; (ii) a cysteine residue (C) at Kabat hinge position 239; (iii) a proline residue (P) at Kabat hinge position 240; (444 iv) a proline (P) or serine (5) residue at Kabat hinge position 241; (v) the human IgG3 middle hinge sequence CPEPKSCDTPPPCPR (SEQ ID NO:37) at Kabat hinge positions 241EE-241SS; and (vi) a cysteine residue (C) at Kabat hinge position 242.

2. The composition of claim 1 , wherein greater than 90% of the polypeptide dimers are linked via at least one interchain disulfide linkage.

3. The composition of claim 1 , wherein the chimeric hinge further comprises a gly-ser linker.

4. The composition of claim 3 , wherein the gly-ser linker consists of the amino acid sequence GGGSSGGGSG (SEQ ID NO:1).

5. The composition of claim 1 , wherein the polypeptide dimers are linked via two or more interchain disulfide linkages.

6. The composition of claim 1 , wherein the heavy chain is from an antibody of an isotype selected from the group consisting of: IgG1, IgG2, IgG3, and IgG4.

7. The composition of claim 1 , wherein the polypeptide dimers comprise four polypeptide chains and wherein two of the polypeptide chains comprise at least one heavy chain and a chimeric hinge.

8. The composition of claim 1 , wherein at least one antigen binding site binds to an antigen expressed by tumor cells.

9. The composition of claim 1 wherein the chimeric hinge is the amino acid sequence of SEQ ID NO:8.

10. The composition of claim 1 , wherein the chimeric hinge is the amino acid sequence of SEQ ID NO:9.

11. The composition of claim 1 , wherein the chimeric hinge is the amino acid sequence of SEQ ID NO:53.

12. A connecting peptide comprising the amino acid sequence SEQ ID NO:8.

13. A connecting peptide comprising the amino acid sequence SEQ ID NO:9.

14. A connecting peptide comprising the amino acid sequence SEQ ID NO:10.

15. A connecting peptide comprising the amino acid sequence SEQ ID NO:11.

16. A connecting peptide comprising the amino acid sequence SEQ ID NO:12.

17. A connecting peptide comprising the amino acid sequence SEQ ID NO:13.

18. A connecting peptide comprising the amino acid sequence SEQ ID NO:14.

19. A connecting peptide comprising the amino acid sequence SEQ ID NO:15.

20. A connecting peptide comprising the amino acid sequence SEQ ID NO:53.

21. A connecting peptide consisting of the amino acid sequence SEQ ID NO:7.

22. A connecting peptide consisting of amino acid sequence SEQ ID NO:8.

23. A connecting peptide consisting of amino acid sequence SEQ ID NO:9.

24. A connecting peptide consisting of amino acid sequence SEQ ID NO:10.

25. A connecting peptide consisting of amino acid sequence SEQ ID NO:11.

26. A connecting peptide consisting of amino acid sequence SEQ ID NO:12.

27. A connecting peptide consisting of amino acid sequence SEQ ID NO:13.

28. A connecting peptide consisting of amino acid sequence SEQ ID NO:14.

29. A connecting peptide consisting of amino acid sequence SEQ ID NO:15.

30. A connecting peptide consisting of amino acid sequence SEQ ID NO:53.

31. A composition comprising polypeptide dimers having at least two antigen binding sites and at least two polypeptide chains, wherein said at least two polypeptide chains each comprise (i) an Ig heavy chain lacking modified to lacking a CH2 domain, and (ii) a synthetic connecting peptide comprising a chimeric hinge,

wherein said connecting peptide is selected from the group consisting of SEQ ID NO: 7-15 and 53 and wherein said connecting peptide connects said heavy chain to at least one of said binding sites, and

wherein greater than 50% of the polypeptide dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.

32. The composition of claim 6 , wherein the heavy chain is from an IgG3 molecule.

33. The composition of claim 6 , wherein the heavy chain is from an IgG4 molecule.

34. The composition of claim 31 , wherein greater than 90% of the polypeptide dimers are linked via at least one interchain disulfide linkage.

35. The composition of claim 31 , wherein the heavy chain is from an antibody of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

36. The composition of claim 31 , wherein the polypeptide dimers comprise four polypeptide chains and wherein two of the polypeptide chains comprise at least one heavy chain and a synthetic connecting peptide.

37. The composition of claim 31 , wherein at least one antigen binding site binds to an antigen expressed by tumor cells.

38. The composition of claim 31 , wherein the heavy chain is from an antibody of an IgG3 isotype.

Assignments (1)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →